Plasma and Urine Samples From Patients With Hormone-Refractory Prostate Cancer Enrolled on Clinical Trials CALGB-9480 or CALGB-9583

OBJECTIVES:

Primary

- Correlate plasma and urine vascular endothelial growth factor (VEGF) levels with
survival duration in patients with advanced hormone-refractory adenocarcinoma of the
prostate previously enrolled on CALGB-9480.

- Determine whether plasma chromogranin A (CgA) and plasma interleukin-6 (IL-6) levels
predict survival duration in these patients.

- Determine whether plasma human Kallikrein 2 (hK2) levels are prognostic for overall
survival of these patients.

Secondary

- Determine the prognostic significance of plasma and urine VEGF levels, plasma CgA
levels, plasma IL-6 levels, and plasma hK2 levels in relation to overall survival of
these patients.

- Correlate plasma VEGF levels with urine VEGF levels in these patients.

- Correlate plasma CgA levels with previously measured serum prostate-specific antigen
(PSA) and plasma VEGF levels in these patients.

- Correlate plasma hK2 levels with PSA changes after treatment with suramin to determine
if hK2 may have predictive value, independent or additive to measures of disease
response in these patients.

- Correlate plasma hK2 levels with PSA levels in these patients.

OUTLINE: Plasma from patients is collected for measurement of the following biomarkers:
vascular endothelial growth factor (VEGF), chromogranin A, interleukin-6, and human
Kallikrein 2. Urine is collected for VEGF measurement.

- Registration to CALGB 9480 or 9583

- Samples collected and shipped appropriately

- Institutional Review Board (IRB) review and approval at the institution where the
laboratory work will be performed is required